🔴 Illumina is trading 4.13% down today after Q3 revenue missed estimates

Illumina is trading at $226.25, down 4.13%, after third-quarter revenue missed analyst estimates.

• Its October 29 report showed revenue of $1.13 billion, below analyst estimates, despite an earnings beat and raised full-year guidance.
• Illumina raised 2026 revenue guidance to $4.64–$4.66 billion and EPS guidance to $5.40–$5.45; organic revenue growth guidance remained above 4%.
• Biotech shares are lower, while the broader market is higher, making sector weakness a possible additional headwind.